Virpax Pharmaceuticals (NASDAQ:VRPX) Board Member Resigns – 8-K Filing Reveals

On December 6, 2024, Virpax Pharmaceuticals, Inc. announced through an 8-K filing submitted to the Securities and Exchange Commission that Mr. Gary Herman, a member of the Board of Directors, tendered his resignation from the Board and all associated committees, effective immediately.

The resignation of Mr. Herman, as stated in the filing, was not prompted by any disagreements with Virpax Pharmaceuticals, its management, the Board, or any operational matters, policies, or practices of the Company. The Company acknowledged and expressed appreciation for Mr. Herman’s service and contributions during his tenure on the Board.

Furthermore, Virpax Pharmaceuticals, a Delaware-based company trading under the symbol VRPX on The Nasdaq Capital Market, confirmed its status as an emerging growth company, meeting the criteria set forth in Rule 405 of the Securities Act of 1933.

Regarding financial disclosures, the 8-K filing also included details of the resignation in Item 5.02 and confirmed the submission of the necessary Exhibits, with Exhibit 104 specifically outlining the Cover Page Interactive Data File embedded within the Inline XBRL document.

As per the requirements of the Securities Exchange Act of 1934, the 8-K filing was signed on behalf of Virpax Pharmaceuticals, Inc. by Jatinder Dhaliwal, the Chief Executive Officer, on December 13, 2024.

With this recent development in the Board of Directors, Virpax Pharmaceuticals continues its operations under the leadership of its executive team.

This article is based on information disclosed in the recent 8-K filing submitted to the SEC by Virpax Pharmaceuticals, Inc.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Virpax Pharmaceuticals’s 8K filing here.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.